Clinical Trials Logo

Clear Cell Renal Cell Carcinoma clinical trials

View clinical trials related to Clear Cell Renal Cell Carcinoma.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03149159 Withdrawn - Clinical trials for Metastatic Renal Cell Carcinoma

Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab

Start date: April 1, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to see if continued nivolumab with the addition of ipilimumab plus hypo-fractionated stereotactic radiation (sTR) of a single lesions results in partial or complete responses in patients with metastatic ccRCC who fail initial treatment with single agent nivolumab.

NCT ID: NCT03035630 Withdrawn - Kidney Cancer Clinical Trials

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

Start date: May 23, 2017
Phase: Phase 2
Study type: Interventional

This is an open label, randomized phase II trial. Eligible subjects will be randomized in a 1:1 ratio and stratified for known prognostics variables to one of two first-line medication treatment arms. Once disease progression has been documented, and following a required inter-line washout period, subjects will receive either second-line medication treatment or discontinue treatment, per discretion of treating investigator.

NCT ID: NCT02307474 Withdrawn - Clinical trials for Renal Cell Carcinoma

A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer

Start date: September 2015
Phase: N/A
Study type: Interventional

This pilot clinical trial studies the side effects of stereotactic body radiation therapy and pazopanib hydrochloride in treating patients with kidney cancer who are not able to undergo surgery. Stereotactic body radiation therapy is a specialized radiation therapy that delivers high doses of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue. Pazopanib hydrochloride may stop the growth of tumor cells by blocking an enzyme needed for cell growth. Giving pazopanib hydrochloride before stereotactic body radiation therapy may help make the tumor smaller and be an alternative treatment for patients who cannot undergo surgery.

NCT ID: NCT01642095 Withdrawn - Clinical trials for Clear Cell Renal Cell Carcinoma

Studying Biomarkers in Samples From Younger Patients With Kidney Cancer

Start date: August 22, 2012
Phase:
Study type: Observational

This laboratory study is looking into biomarkers in samples from younger patients with kidney cancer. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat cancer.